The additional two years of patent protection will apply only to drugs approved after the deal is passed, International Trade Minister Ed Fast wrote in a letter to Keon.
The trade deal does include some provisions that will help generic drug manufacturers, including an exception allowing them to continue to produce and market drugs they are exporting to countries with shorter patent protection periods. In addition, the federal government has promised to simplify the patent litigation process, which Keon believes will reduce costs for the generic industry.
"We're hoping that if the system is actually simplified, some of the litigation costs can go into product development and that might actually help our industry," he says.
Overall, the trade deal's intellectual property provisions required Canada to make changes while the European Union does not have to change anything about its patent protection regime. "In pharmaceuticals, this was a net loss for Canada," says Keon. "I think what the government is saying is that it needed to do that in order to get the Europeans to agree to other provisions of the deal."
Representatives of the brand-name pharmaceutical manufacturers welcome the agreement, saying the increased patent protection compensates for a lengthy regulatory and government approval process and creates a "more level playing field" in intellectual property protection. But Russell Williams, president of RX&D, the association that represents brand-name drug makers, insists it is impossible to know for sure if the changes will mean consumers paying more money -either in taxes or out-of-pocket -for drugs. "Intellectual property does not drive cost," Williams writes in an email. "Europe, for example, benefits from better intellectual property protection than Canada, but has implemented other effective methods to control innovative and generic medicine costs, which are also available to our governments."
The changes proposed as part of the trade agreement will be implemented over as many as 10 years, "on medicines that don't even exist today," he writes. "We will continue to work with governments and private drug plans to ensure that Canadians have access to the next generation of new medicines in a sustainable way."
The agreement will stimulate additional investment and more clinical trials in Canada, Williams writes.
"More clinical trials in Canada mean more chances for patients to benefit from potentially life-saving or lifechanging medicines."
Before the agreement takes effect, all 28 EU nations as well as all the provinces and territories must approve it. The process could take up to two years. -Laura Eggertson, CMAJ 
Canada-EU trade agreement expected to increase drug costs
The trade agreement will effectively extend patents for brandname pharmaceuticals to 22 years from the current 20, limiting the market for cheaper generic drugs.
